6. Parkinson disease Clinical trials / Disease details
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03659682 (ClinicalTrials.gov) | January 2, 2019 | 3/9/2018 | GLP1R in Parkinson's Disease | Effect of GLPIR Stimulation on Neuroprotection and Inflammation in Parkinson's Disease | Parkinson Disease | Drug: Semaglutide | Oslo University Hospital | NULL | Not yet recruiting | 40 Years | 75 Years | All | 120 | Phase 2 | NULL |